GlassScriptPhysician profile
William P Buckley
NPI 1922001098
$10,809.25
in general payments reported to CMS, 2019-2025
58 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,247 · 2020: $323 · 2021: $717 · 2022: $1,129 · 2023: $1,894 · 2024: $2,288 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,375 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,374.53 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,249.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $932.46 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $925.46 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $878.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $750.67 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Pfizer INC. | $569.37 | 2019-2025 | |
| Abbvie INC. | $564.25 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $560.74 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $496.40 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $382.27 | 2019-2022 | |
| Astellas Pharma US INC | $334.24 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $322.73 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $305.18 | 2023-2025 | Ingrezza |
| Sumitomo Pharma America, INC. | $284.94 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $273.40 | 2019-2024 | Xarelto |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buckley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.